Device Trial Radar · NCT02108496
Verifying the Effectiveness of the NUsurface® System
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
337
Actual
Start
Jul 2014
Primary completion
Jun 2021
Study completion May 3, 2022
Sponsor
- Lead sponsor
- Phoenix KineticsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 9, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The NUsurface® Meniscus Implant Randomized Study is a multi-center, prospective randomized, interventional clinical trial to test the hypothesis that the NUsurface implant is superior to the non-surgical standard of care in treating the target population.The rationale for performing this clinical study is to gather clinical data to evaluate the safety and effectiveness of the NUsurface device compared to the Standard of Care.
Conditions
- Meniscectomy
- Osteoarthritis
Interventions
NUsurface® Meniscus ImplantDevice
The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
NSAID's and Non-surgical Treatment OptionsDrug
Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
Intra-Articular Injections with CorticosteroidsDrug
Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
Intra-Articular Injections with Hyaluronic Acid (HA)Drug
Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Success Composite EndpointTime frame: 2 years
- Automatic Study FailureTime frame: 2 Years
- KOOS SuccessTime frame: 2 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
OrthoIndy
Indianapolis, Indiana
Brigham and Woman's Hospital
Boston, Massachusetts
New England Baptist Hospital
Roxbury Crossing, Massachusetts
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.